Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentric Single Arm Phase II Study Evaluating the Efficacy of Association of Tucatinib, Capecitabine and Intra-CSF Trastuzumab in HER2 Amplified Breast Cancer Patients With Leptomeningeal Metastases

NCT05800275 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT05800275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05800275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentric Single Arm Phase II Study Evaluating the Efficacy of Association of Tucatinib, Capecitabine and Intra-CSF Trastuzumab in HER2 Amplified Breast Cancer Patients With Leptomeningeal Metastases
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Recruiting
Start date
December 18, 2023
Completion date
June 30, 2027
Enrollment
30 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive metastatic breast cancer, leptomeningeal disease, leptomeningeal metastasis